However, quantitative comparisons of the efficacy of these GLP-1 receptor agonist drugs in obesity treatment, particularly between mono-, dual-, and triple-agonists, are still lacking. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.